Is an EMA review on hormonal contraception and thrombosis needed?: Sufficient evidence exists to recommend the second generation pill with the lowest tolerable oestrogen dose for all indications

BMJ (Online)

Volumn 346, Issue 7899, 2013, Pages

  Helmerhorst, Frans M ^a   Rosendaal, Frits R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DROSPIRENONE; ETHINYLESTRADIOL; GESTAGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ACNE; ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; DRUG FATALITY; DRUG INDICATION; DRUG TOLERANCE; EDITORIAL; HIRSUTISM; HORMONAL CONTRACEPTION; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; SIDE EFFECT; THROMBOSIS; VEIN THROMBOSIS; WEIGHT GAIN;

CONTRACEPTIVES, ORAL, HORMONAL; EUROPEAN UNION; FEMALE; GOVERNMENT AGENCIES; HUMANS; PATIENT SAFETY; THROMBOSIS;

EID: 84875190045     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f1464     Document Type: Editorial

References (12)

1. Arie S. French doctors are told to restrict use of third and fourth generation oral contraceptives. BMJ 2013; 346:f121.
2. Benkimoun P, Cabut S. Pilules de 3e et 4e génération: la surveillance des médicaments à nouveau prise en défaut. Le Monde 2013 Jan 15. www.lemonde.fr/sante/article/2013/01/10/la-surveillance-des- medicaments-a-nouveau-prise-en-defaut-1814859-1651302.html.
3. European Medicines Agency. Combined hormonal contraceptives. 2013. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/ Combined-hormonal-contraceptives/human-referral-prac-000016.jsp&mid= WC0b01ac05805c516f.
4. European Medicines Agency. Cyproterone- and ethinylestradiol-containing medicines. 2013. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ referrals/Cyproterone-and-ethinylestradiol-containing-medicinal-products/ human-referral-prac-000017.jsp&mid=WC0b01ac05805c516f.
5. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339:b2921.
6. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366:2257-66.
7. Vasilakis-Scaramozza C., Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358:1427-9. (Pubitemid 33055749)
8. Van Grootheest K., Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ 2003; 326:257. (Pubitemid 36169591)
9. Arowojolu AO, Gallo MF, Lopez L.M., Grimes DA Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 7:CD004425.
10. Gallo MF, Lopez LM, Grimes D.A., Schulz KF, Helmerhorst FM Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2011; 9:CD003987.
11. Gallo MF, Nanda K, Grimes D.A., Lopez LM, Schulz KF 20 μg versus >20 μg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2011; 1:CD003989.
12. Dunn N. The risk of deep venous thrombosis with oral contraceptives containing drospirenone. BMJ 2011; 342:d2519.